Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
CAPRICOR THERAPEUTICS INC (CAPR) Stock Price & Overview
NASDAQ:CAPR • US14070B3096
Current stock price
30.91 USD
-2.67 (-7.95%)
At close:
31.3612 USD
+0.45 (+1.46%)
After Hours:
The current stock price of CAPR is 30.91 USD. Today CAPR is down by -7.95%. In the past month the price decreased by -3.74%. In the past year, price increased by 160.62%.
CAPR Key Statistics
52-Week Range4.3 - 40.37
Current CAPR stock price positioned within its 52-week range.
1-Month Range29.58 - 36.82
Current CAPR stock price positioned within its 1-month range.
- Market Cap
- 1.788B
- P/E
- N/A
- Fwd P/E
- 284.09
- EPS (TTM)
- -2.26
- Dividend Yield
- N/A
CAPR Stock Performance
Today
-7.95%
1 Week
-12.36%
1 Month
-3.74%
3 Months
+41.21%
Longer-term
6 Months +374.81%
1 Year +160.62%
2 Years +444.19%
3 Years +582.34%
5 Years +715.57%
10 Years -3.10%
CAPR Stock Chart
CAPR Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to CAPR. When comparing the yearly performance of all stocks, CAPR is one of the better performing stocks in the market, outperforming 95.82% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
CAPR Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to CAPR. CAPR has a great financial health rating, but its profitability evaluates not so good.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
CAPR Earnings
Next Earnings DateMay 7, 2026
Last Earnings DateMar 12, 2026
PeriodQ4 / 2025
EPS Reported-$0.62
Revenue Reported
EPS Surprise -12.56%
Revenue Surprise %
CAPR Forecast & Estimates
16 analysts have analysed CAPR and the average price target is 55.76 USD. This implies a price increase of 80.39% is expected in the next year compared to the current price of 30.91.
For the next year, analysts expect an EPS growth of 104.81% and a revenue growth 19640.8% for CAPR
Analysts
Analysts83.75
Price Target55.76 (80.39%)
EPS Next Y104.81%
Revenue Next Year19640.8%
CAPR Index Membership
CAPR is currently included in the following stock indexes tracked on ChartMill.
CAPR Financial Highlights
Over the last trailing twelve months CAPR reported a non-GAAP Earnings per Share(EPS) of -2.26. The EPS decreased by -88.33% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-105.04M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.51% | ||
| ROE | -34.35% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-287.5%
Sales Q2Q%-100%
EPS 1Y (TTM)-88.33%
Revenue 1Y (TTM)-100%
CAPR Ownership
Ownership
Inst Owners54.07%
Shares57.84M
Float52.36M
Ins Owners0.93%
Short Float %19.17%
Short Ratio7.55
CAPR Industry Overview
CAPR operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.2
CAPR Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CAPR
Company Profile
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. The company is headquartered in San Diego, California. The company went IPO on 2002-06-04. The firm's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.
Company Info
IPO: 2002-06-04
CAPRICOR THERAPEUTICS INC
10865 Road to the Cure, Suite 150
San Diego CALIFORNIA 90211 US
CEO: Linda Marban
Employees: 231
Phone: 13103583200
CAPRICOR THERAPEUTICS INC / CAPR FAQ
What does CAPR do?
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. The company is headquartered in San Diego, California. The company went IPO on 2002-06-04. The firm's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.
What is the current price of CAPR stock?
The current stock price of CAPR is 30.91 USD. The price decreased by -7.95% in the last trading session.
Does CAPRICOR THERAPEUTICS INC pay dividends?
CAPR does not pay a dividend.
How is the ChartMill rating for CAPRICOR THERAPEUTICS INC?
CAPR has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the expected growth for CAPR stock?
The Revenue of CAPRICOR THERAPEUTICS INC (CAPR) is expected to grow by 19640.8% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for CAPR stock?
CAPRICOR THERAPEUTICS INC (CAPR) currently has 231 employees.
What is the market capitalization of CAPR stock?
CAPRICOR THERAPEUTICS INC (CAPR) has a market capitalization of 1.79B USD. This makes CAPR a Small Cap stock.